GLP-1 Market Top Companies Study - AstraZeneca, Biolingus, Boehringer Ingelheim, D&D Pharmatech.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global GLP-1 Market Size, Share & Trends Analysis Report By Type of Molecule (Biologics and Small Molecules), Active Compound Used (Dulaglutide, Liraglutide, Orforglipron, Retatrutide, Semaglutide, Survodutide, Tirzepatide and Other Active Compounds), Type of GLP-1 Agonist Drugs (Long-acting GLP-1 Agonist and Short-acting GLP-1 Agonist), Type of Agonist (Single-agonist, Dual-agonist and Tri-agonist), Route of Administration (Oral and Parenteral), Target indication (Alzheimer's Disease, Non-Alcoholic Steatohepatitis, Obesity, Sleep Apnea, Type 2 Diabetes)- Market Outlook And Industry Analysis 2034"

The Global GLP-1 Market is valued at USD 50.0 Billion in 2024, and it is expected to reach USD 141.9 Billion by the year 2034, with a CAGR of 11.1% during the forecast period of 2025-2034..

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2592

Glucagon-like peptide-1 (GLP-1) is an endogenous hormone produced in the gastrointestinal tract that plays a pivotal role in regulating blood glucose levels and appetite. GLP-1 receptor agonists are pharmacological agents designed to activate GLP-1 receptors, delivering multiple clinically advantageous effects. These include stimulating insulin secretion from pancreatic beta cells in response to elevated glucose, suppressing glucagon release, slowing gastric emptying, and enhancing glucose uptake in peripheral tissues.

As a result, GLP-1 receptor agonists have demonstrated substantial efficacy in managing type 2 diabetes while offering the additional benefit of weight reduction, a key consideration for many patients. Certain GLP-1 receptor agonists have also obtained regulatory approval for obesity treatment due to their appetite-suppressing and weight-loss effects.

The GLP-1 receptor agonist market encompasses both approved and investigational therapies. Prominent examples include short-acting agents such as exenatide and lixisenatide, alongside long-acting formulations including semaglutide, dulaglutide, and liraglutide. Oral therapies, notably oral semaglutide (Rybelsus), provide further flexibility in treatment administration.

Additionally, next-generation agents, including dual and tri-agonists such as tirzepatide that target multiple hormonal pathways, are under active development. Market growth is primarily driven by the increasing global prevalence of type 2 diabetes and obesity, combined with the established efficacy and safety of existing GLP-1 therapies. Continued innovation and pharmaceutical advancements are expected to expand the therapeutic landscape, supporting sustained growth in the GLP-1 receptor agonist market in the coming years.

List of Prominent Players in the GLP-1 Market:
• AstraZeneca
• Biolingus
• Boehringer Ingelheim
• D&D Pharmatech
• Eli Lilly
• Gmax Biopharm
• Hanmi Pharmaceutical
• Innogen
• Novo Nordisk
• PegBio
• Pfizer
• QL Biopharma
• Roche
• Sanofi
• Sciwind Biosciences
• Tonghua Dongbao Pharmaceutical
• Viking Therapeutics
• Vivani
• vTv Therapeutic

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02

Market Dynamics
Drivers:
The escalating prevalence of type 2 diabetes and obesity is a primary driver of growth in the GLP-1 receptor agonist market. Data published in the Journal of the American Medical Association indicate that diabetes prevalence increased from 3.0% to 4.1%, while obesity rates rose from 32.7% to 40.9% between 2009 and 2020. GLP-1 receptor agonists have demonstrated strong clinical efficacy in lowering blood glucose levels, reducing HbA1c, and supporting significant weight loss.

Regulatory approvals, such as semaglutide (Wegovy) for obesity in addition to diabetes, have expanded the eligible patient population, further accelerating market growth. Enhancements in insurance coverage and affordability are improving patient access, while innovations in drug delivery-including oral formulations and once-weekly injectables-are increasing treatment convenience and adherence, addressing critical gaps in diabetes and obesity management.

Challenges:
Despite their therapeutic advantages, GLP-1 receptor agonists face several constraints. Gastrointestinal side effects, such as nausea and vomiting, may negatively impact patient adherence over the long term. Although once-weekly injectable formulations improve convenience, the requirement for subcutaneous administration continues to pose a barrier for certain patients. While oral therapies, such as semaglutide, enhance accessibility, there remains a demand for longer-acting agents with less frequent dosing. High treatment costs and inconsistent insurance coverage, particularly in low- and middle-income countries, further limit market penetration, emphasizing the need for more affordable and widely accessible therapeutic options.

Regional Trends:
The Asia-Pacific (APAC) region is emerging as a high-growth market for GLP-1 receptor agonists, with key contributions from China, India, and Japan. Market expansion is driven by the rising burden of diabetes and obesity, improvements in healthcare infrastructure, and a substantial underserved patient population. The increasing prevalence of metabolic disorders is generating strong demand for advanced therapeutic solutions. In response, leading pharmaceutical companies are intensifying investment in innovative GLP-1 therapies and expanding their commercial operations to better address the evolving healthcare needs of the region.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2592

Recent Developments:
• In November 2023, The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's ZepboundTM (tirzepatide) injection, marking it as the first and only obesity treatment that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.
• In Dec 2021, Shanghai Innogen Pharma successfully completed a $120 million Series A funding round to support its Phase III trial of supaglutide, a GLP-1 agonist targeting diabetes. The funds will also be used to advance several first-in-class programs and establish a clinical trial manufacturing facility.

Segmentation of GLP-1 Market-
By Type of Molecule:
• Biologics
• Small Molecules
By Active Compound Used:
• Dulaglutide
• Liraglutide
• Orforglipron
• Retatrutide
• Semaglutide
• Survodutide
• Tirzepatide
• Other Active Compounds
By Type of GLP-1 Agonist Drugs:
• Long-acting GLP-1 Agonist
• Short-acting GLP-1 Agonist
By Type of Agonist:
• Single agonist
• Dual agonist
• Tri-agonist
By Route of Administration:
• Oral
• Parenteral
By Target Indication:
• Alzheimer's Disease
• Non-Alcoholic Steatohepatitis
• Obesity
• Sleep Apnea
• Type 2 Diabetes
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/glp-1-market/2592

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.